Octant
Octant is a biotechnology company focused on developing next-generation small molecule therapeutics by integrating synthetic biology, high-throughput chemistry, and advanced data analytics.
Company Overview
Octant focuses on navigating the complexity of biology and chemistry to develop next-generation small molecules. The company aims to map a new universe of medicine with bold new approaches that are native to biology. By leveraging cutting-edge technology platforms, Octant harnesses high-throughput synthetic biology, barcoded multiplexing, and AI/ML pipelines to drive advanced drug development programs.
Technology Platform
Octant utilizes various state-of-the-art technologies to advance the development of small molecule therapeutics. High-throughput synthetic biology is employed to disentangle and model complex cellular mechanisms driving disease. The company also integrates high-throughput chemistry to engineer small molecules that can modulate these biological mechanisms. Additionally, Octant uses barcoded multiplexing for massively parallel high-throughput drug discovery, alongside big data and AI/ML pipelines to accelerate drug development programs.
Leadership Team
On December 12, 2023, Octant announced the appointment of Chris Sinz, Matthew Albert, Rebecca Velez Frey, and Wen-Chen Yeh to key leadership positions. These additions to the leadership team are expected to support the company's mission and strategic objectives. Each leader brings a wealth of experience and expertise that will help guide Octant's continued growth and innovation in the field of small molecule therapeutics.
Awards and Recognition
In 2022, Octant received the 'Technology and Tools' Award at the Mutational Scanning Symposium. This accolade recognizes the company's advancements and contributions to the field of high-throughput drug discovery and synthetic biology. Octant's innovative technology continues to garner industry recognition and validation.
Funding and Partnerships
On April 21, 2022, Octant successfully raised $80M in Series B funding. This significant financial milestone was complemented by the establishment of a strategic partnership with Bristol Myers Squibb (BMS). The collaboration aims to leverage Octant's cutting-edge technology platform to accelerate the discovery and development of next-generation small molecule therapeutics.